Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company ...

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a biopharmaceutical company specializing in the development of RNAi therapeutics, with a diverse pipeline and strong partnerships within the industry.

An Arrowhead Pharmaceuticals “gene-silencing” drug that the biotech has been quietly researching as a gout treatment will continue its development under a partnership with Horizon Therapeutics.

Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 [email protected] ...

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a small-cap biopharma that is developing a line therapies utilizing RNA interference (RNAI) to silence disease-causing genes. While the company has yet ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TIDES USA 2022 ...